Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1

Evangelos Kiskinis, Jackson Sandoe, Luis A. Williams, Gabriella L. Boulting, Rob Moccia, Brian J. Wainger, Steve Han, Theodore Peng, Sebastian Thams, Shravani Mikkilineni, Cassidy Mellin, Florian T. Merkle, Brandi N. Davis-Dusenbery, Michael Ziller, Derek Oakley, Justin Ichida, Stefania Di Costanzo, Nick Atwater, Morgan L. Maeder, Mathew J. GoodwinJames Nemesh, Robert E. Handsaker, Daniel Paull, Scott Noggle, Steven A. McCarroll, J. Keith Joung, Clifford J. Woolf, Robert H. Brown, Kevin Eggan*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

296 Scopus citations

Abstract

Although many distinct mutations in a variety of genes are known to cause Amyotrophic Lateral Sclerosis (ALS), it remains poorly understood how they selectively impact motor neuron biology and whether they converge on common pathways to cause neuronal degeneration. Here, we have combined reprogramming and stem cell differentiation approaches with genome engineering and RNA sequencing to define the transcriptional and functional changes that are induced in human motor neurons by mutant SOD1. Mutant SOD1 protein induced a transcriptional signature indicative of increased oxidative stress, reduced mitochondrial function, altered subcellular transport, and activation of the ER stress and unfolded protein response pathways. Functional studies demonstrated that these pathways were perturbed in a manner dependent on the SOD1 mutation. Finally, interrogation of stem-cell-derived motor neurons produced from ALS patients harboring a repeat expansion in C9orf72 indicates that at least a subset of these changes are more broadly conserved in ALS.

Original languageEnglish (US)
Pages (from-to)781-795
Number of pages15
JournalCell stem cell
Volume14
Issue number6
DOIs
StatePublished - Jun 5 2014

Funding

We thank H. Mitsumoto and D. McKenna-Yasek for performing skin biopsies; K. Koszka for maintaining mice; all members of the Eggan Lab; and C. Henderson and M.W. Amoroso for helpful comments on the manuscript. R.H.B. acknowledges generous support from the ALS Therapy Alliance, Project ALS, P2ALS, the Angel Fund, the Pierre L. de Bourgknecht ALS Research Foundation, the Al-Athel ALS Research Foundation, the ALS Family Charitable Foundation, and the NIH/NINDS (1R01NS050557 and NINDS ARRA Award RC2-NS070-342). This work was funded by Target ALS, Project A.L.S., P2ALS, NINDS GO grant (5RC2NS069395-02), NINDS R24 (1U24NS078736-01), the HHMI, and the NIH Director’s Pioneer Award DP1 (OD006862). E.K. is a Charles A. King Trust Postdoctoral fellow, and K.E. is an HHMI early career scientist. J.K.J. has financial interests in Editas Medicine and Transposagen Biopharmaceuticals. J.K.J.'s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Cell Biology

Fingerprint

Dive into the research topics of 'Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1'. Together they form a unique fingerprint.

Cite this